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ABSTRACT 
OBJECTIVE 
To evaluate the association between severe adverse outcomes and the antibiotic treatment for 
urinary tract infection (UTI) diagnosed in elderly adults in primary care.  
DESIGN 
A retrospective population-based cohort study. 
SETTING 
Clinical Practice Research Datalink (2007-2015) primary care records linked to Hospital 
Episode Statistics and death records in England. 
PARTICIPANTS 
Patients aged≥65 years presenting to a General Practitioner (GP) with at least one diagnosis 
of suspected or confirmed lower UTI from November 2007 to May 2015. 
MAIN OUTCOME MEASURES 
Bloodstream infection (BSI), hospital admission and all-cause mortality within 60 days 
following the index UTI diagnosis. 
RESULTS 
Among 312,896 UTI episodes (157,264 unique patients), 7% did not have a record of having 
been prescribed antibiotics and 6% showed a delay in antibiotic prescribing. 1,539 episodes of 
BSI were recorded within 60 days following the initial UTI.  
The rate of BSI was significantly higher among those patients who were not prescribed an 
antibiotic (2. 9%) and those patients recorded as returning to the GP within 7 days of the initial 
consultation for an antibiotic prescription (2.2%), compared with those given a prescription for 
an antibiotic at the initial consultation (0.2%) (p=0.001). After adjustment for covariates, 
patients were significantly more likely to experience a BSI in the ‘deferred antibiotics’ and ‘no 
antibiotics’ groups compared with the ‘immediate antibiotics’ group (aOR=7.12 [95% CI 6.22 
to 8.14] and aOR=8.08 [95% CI 7.12 to 9.16]). 
The Number Needed to Harm (NNH) for occurrence of BSI was lower (greater risk) for the 
‘no antibiotics’ group (NNH=37) than for the ‘deferred antibiotics’ group (NNH=51), relative 
to the ‘immediate antibiotics’ group. The rate of hospital admissions was approximately double 
among cases with ‘no antibiotics’ (27%) and ‘deferred antibiotics’ (27%) compared with those 
prescribed ‘immediate antibiotics' (15%) (p=0.001). The risk of all-cause mortality was 
significantly higher with ‘deferred antibiotics’ and ‘no antibiotics’ than with ‘immediate 
antibiotics’ at any time during the 60 days follow-up (aHR=1.16 [95% CI, 1.06 to 1.27] and 
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aHR=2.18 [95% CI, 2.04 to 2.33], respectively). Male patients over 85 years of age were 
particularly at risk for both BSI and 60 day all-cause mortality. 
CONCLUSIONS 
There was a significant increase in BSI and all-cause mortality associated with ‘no 
antibiotics’ and ‘deferred antibiotics’ compared with ‘immediate antibiotics’ in elderly adults 
diagnosed with UTI in primary care. In the context of an increase of E. coli BSIs in England, 
early initiation of recommended first-line antibiotics for UTI in the older adult population is 
advocated.  
 
 
 
Introduction 
Urinary tract infection (UTI) is the most frequent bacterial infection in the older patient 
population, and the most common uropathogen in community-dwelling adults over the age of 
65 years old is Escherichia coli.1  The spectrum of UTI ranges from a mild self-limiting 
WHAT IS ALREADY KNOWN ON THIS TOPIC 
Gram-negative BSIs are increasing significantly in England. Approximately half of 
Escherichia coli BSIs are caused by an underlying UTI. Older age is an independent risk 
factor for UTI-related BSI and its associated mortality. While evidence suggests that ‘no 
antibiotic’ and ‘delayed or deferred antibiotic’ treatment approaches are often not 
associated with severe adverse outcomes for some self-limiting illnesses (e.g. upper 
respiratory tract infections, acute non-pneumonic lower respiratory infections, acute otitis 
media and conjunctivitis), a slight increase in symptom duration and complication rate 
with these two therapeutic approaches have been reported for UTI in young women. The 
generalisability of these studies, however, is limited because of sample size and study 
population demographics.  
WHAT THIS STUDY ADDS 
After adjustment for key covariates, ‘no antibiotics’ and ‘deferred antibiotic’ approaches 
for the management of UTI in older adults in primary care appears to be associated with a 
significant increased risk of BSI and all-cause mortality compared with an ‘immediate 
antibiotics’ approach. 
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illness to severe sepsis with a mortality rate of 20-40%. The incidence of sepsis and its 
associated mortality increases disproportionately with age and UTI in men is more likely to 
be severe.2-4 Both sexes develop UTI in old age, with a 2:1 female to male ratio in patients 
over 70 years of age, compared with the overwhelming UTI susceptibility of females in 
younger populations, with a 50:1 ratio.5 The diagnosis of UTI in older patients can be 
difficult, however, as they are less likely to present with a typical clinical history and 
localised urinary symptoms compared with younger patients.6 The rising incidence of 
asymptomatic bacteriuria in older adults is also contributing to further diagnostic difficulty 
(more than 20% of women ≥65 years-old compared with less than 5% in younger age) which 
results in probable over-diagnosis of UTI and unnecessary treatment.6-8  
UTI is the second most common diagnosis for which empirical antibiotics are prescribed in 
both primary and secondary care, with over 50% of the antibiotics prescribed for a suspected 
UTI in older adult patients being deemed unnecessary.9-11 With the spread of antibiotic 
resistance and its increasing threat to public health (about 30% of urinary isolates of E. coli 
are now resistant to trimethoprim), national guidelines and antimicrobial stewardship 
programmes have been proposed to combat these challenges.12-16 NHS England, for example, 
released the Quality Premium to incentivise Clinical Commissioning Groups (CCGs) to 
reduce antibiotic use in primary care.17 As a result of these new initiatives, a significant 
decrease in antibiotic use has been reported for the first time in England across the whole 
healthcare system between 2013 and 2017.16 18 19 A recent study has also demonstrated a 
decrease in broad-spectrum antibiotic prescribing for UTI in older adult patients in primary 
care between 2004 and 2014.20 In the meantime, however, increases in the incidence of 
Gram-negative BSIs have been reported, which has led the UK government to announce a 
plan to reduce healthcare-associated Gram-negative BSIs in England by 50% by March 
2021.16  
As the pattern of antibiotic use changes in the context of antimicrobial resistance, it is now 
more important than ever to assess the management and outcome of UTIs. Clostridium 
difficile in the elderly has also been one of the drivers for scrutiny of unnecessary antibiotic 
exposure in this population. A decline in antibiotic use may however harm vulnerable older 
adult populations who are already more likely to develop UTI-related complications and BSI. 
There is a need for more evidence regarding the initial treatment of UTI in primary care, 
including an assessment of prescribing approaches involving ‘no antibiotics’, ‘deferred 
antibiotics’ or ‘immediate antibiotics’, and the subsequent clinical outcome. This study aims 
to link primary care data in England with hospital admissions and mortality data at a patient 
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level, allowing a pragmatic approach to assessing the impact of standard care in the 
community for a large cohort of older patients with confirmed or suspected UTI on adverse 
events including hospital admission, BSI and death. 
Methods 
Study design, setting  
We conducted a retrospective population-based cohort study in England on patients attending 
NHS general practitioner (GP) practices submitting data to the UK-based Clinical Practice 
Research Datalink (CPRD) between November 2007 and June 2015.  
Data source 
Anonymous medical patient records were extracted from CPRD, the world’s largest primary 
care electronic health database containing information on a representative national sample. 
About 7% of English NHS GP practices across the country contribute data to this database.21 
CPRD has been extensively used and validated for pharmaco-epidemiological research. 
The CPRD database contains a wide-ranging set of information that includes patient socio-
demographics, medical diagnoses using the READ classification system, outpatient 
prescriptions, physiological and laboratory investigations, health behaviours and referrals to 
secondary care.22 More than 50% of the practices registered with CPRD have agreed to their 
records being linked with the corresponding patient hospital records from the Hospital Episode 
Statistics (HES) database, which contains information on all hospital admissions, together with 
information about the causes of each episode of inpatient care using ICD-10 (International 
Classification of Diseases, 10th revision) for the coding of diagnosis, type of admission, 
procedure performed, length of stay, and discharge status (http://www.hscic.gov.uk/hes). 
Patients’ primary care data were also linked to the Death Registration data from the Office 
for National Statistics (ONS), that contain date and causes of death, and to the 2010 English 
Index of Multiple Deprivation (IMD) data, that contain small area-level measures of relative 
deprivation. For the latter, a proxy for socio-demographic and socio-economic status was 
obtained across numerous domains including housing, employment, income, access to 
services, education and skills, crime, and living environment, using practice postcode for data 
linkage (https://www.cprd.com/dataAccess/linkeddata.asp).  
 
Population 
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All patients aged 65 years or older presenting to a GP with at least one diagnosis of suspected 
or confirmed lower UTI (recorded using a READ code indicating a clinical, test or referral 
event) in the CPRD database, were included in the study (See Supplementary materials, 
Table S1). Patients were excluded if they presented with asymptomatic bacteriuria or had 
missing data for gender. They were also excluded if they were either diagnosed with a 
complicated UTI, admitted to hospital or died on the day as their initial UTI diagnosis.  
All patients included in the study were registered with a practice for at least 12 continuous 
months prior to their first UTI consultation (defined as ‘index’ UTI) to capture potential 
comorbidities and previous medical history. 
A period of 90 days, including 30-day pre-diagnosis and 60-day follow-up post index UTI, 
was used to distinguish distinct episodes of UTI for the same patient. All the GP 
consultations within 60 days of the initial UTI diagnosis were treated as being related to the 
same UTI episode, while a 30-day buffer period before the index date of the second UTI 
episode was used to identify any relevant medical history for this new episode (Figure 1).  
Only practices classified as ‘up-to-standard’ (continuous high-quality data acceptable for use 
in research) a year before the start of the study period were included to ensure data quality. 
Similarly, patient data were only included if an ‘acceptable’ registration status for use in 
research, including contiguous follow up and valid data recording as defined by CPRD, was 
present at the time of the recruitment and during the follow-up period.23 As part of the data 
management process, we have considered all the UTI observations with a same consultation 
date as duplicates. All additional information present in different rows at the same date were 
grouped together under a same GP consultation. 
We further excluded patients for whom primary care medical records were not eligible for 
data linkage with the HES records and patients without a 60-day follow-up period post index 
UTI consultation.  
 
Figure 1: Timeline of the study and criteria for differentiating independent episodes of 
urinary tract infection (UTI) 
 
 
Exposure 
Antibiotic prescribing practices following the initial diagnosis of UTI in primary care were 
considered as the main exposure. Three different approaches for antibiotic exposure were 
defined, comprising ‘immediate antibiotics’ for patients prescribed an antibiotic at their first 
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UTI visit or on the same day; ‘deferred antibiotics’ for patients prescribed an antibiotic in 
primary care within 7 days (to allow for the natural resolution of the disease)24 but not on the 
day of the initial UTI diagnosis and in the absence of complication and/or hospital admission; 
and, ‘no antibiotics’ for patients who were not recorded as having been prescribed an 
antibiotic by the GP within 7 days following the UTI diagnosis or if a complication occurred 
before antibiotics were prescribed. The name of the antibiotic and duration of therapy were 
also collected.  
The ‘deferred antibiotics’ group should capture the post-dated prescriptions given to patient 
on the index date or left behind at the reception to collect on a later date, or the prescriptions 
for patients who have been asked to come back if the symptoms are not improving.  
 
Outcome 
The primary outcomes of interest were: 
- BSI within 60 days following the initial diagnosis, captured in both HES and the 
CPRD database. Our definition of BSI included Read codes and ICD-10 codes related 
to sepsis, septicaemia and bacteraemia (Supplementary materials, Table S1 and 
S2); 
- All-cause mortality within 60 days following the initial UTI diagnosis. 
The secondary outcomes of interest were: 
- Hospital admission within 60 days post UTI diagnosis 
- The length of stay for hospitalised patients during their episode of UTI  
- The type of care pathway experienced by the patient.  
The patients were classified into three different types of care pathways: 1) single primary care 
consultation for a UTI without hospitalisation or complication related to the UTI within 60 
days of the initial diagnosis; 2) multiple primary care consultations for the same episode of 
UTI without hospital admission within 60 days of the initial diagnosis; 3) single or multiple 
primary care consultations for the same UTI episode with a hospital admission, regardless of 
the reason, within 60 days of the UTI diagnosis, and including any UTI-related-complications 
(Table S1 and S2), BSI and death. 
 
Covariates 
A set of covariates were described and used in the models to adjust for potential sources of 
confounding. These included: age (defined as a categorical variable: 65-74, 75-84 and ≥85 
years-old); gender; grouped regions (defined as a categorical variable: North of England and 
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Yorkshire, Midlands and East of England, South of England and London); area-level 
deprivation (IMD) divided in 5 quintiles (first quintile being the least deprived and fifth 
quintile being the most deprived); year of consultations/diagnoses (financial years from May 
to April to account for changes in NHS England quality premium guidance);17 Charlson 
Comorbidity Score (on a scale of 0 to 12 with a higher score indicating an increased risk of 
death within a year) (Supplementary materials, Table S3);25 immuno-suppression; smoking 
status; medical history 30 days before the index UTI (indwelling urethral catheter, 
hospitalisation with a discharge date within the 30 days before the index case, an antibiotic 
treatment (including short-course or prophylactic treatment), presenting symptoms potentially 
related to UTI) and a history of recurrent UTIs. 
 
A recurrent UTI was defined as the presence of a READ code for ‘recurrent UTI’ or 
prophylactic treatment for UTI (trimethoprim or nitrofurantoin prescribed for 28 days or 
more) or ≥2 UTIs within a 12-month period. Although recurrent UTI is usually defined as ≥2 
UTIs within 6 months or ≥3 UTIs within 12 months,26 we adapted this definition to account 
for the 90-day period between each index case to allow for distinct UTI episodes.  
All the binary covariates described above were classified as absence of the condition when 
data were missing.  
 
Statistical analyses 
We first compared patient characteristics and other covariates with different exposures to 
antibiotics. All variables of interest were described using standard measures of central 
tendency and variability i.e. means and standard-deviations for continuous variables and 
counts and percentages for categorical variables. Comparisons between groups were 
performed using a range of tests: Chi-Square and Fisher’s exact for categorical variables, 
analysis of variance (ANOVA) and the Kruskal-Wallis for continuous variables. The rates of 
BSI, hospitalisation and all cause-mortality as well as the average of length of stay for 
hospitalised patients were also compared between the three antibiotic exposure groups. The 
numbers needed to harm (NNH) related to both BSI and death within 60 days, were then 
calculated. This measure indicated the average number of patients needed to be exposed to 
‘no antibiotic’ and ‘deferred antibiotics’ to cause harm in an average of one patient who 
would not otherwise have been harmed if treated with ‘immediate antibiotics’.  
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Differences in the proportion of cases experiencing one of the three care pathways described 
above were stratified by antibiotic exposure, age and gender and compared using the Chi-
Square test. 
The secondary analysis evaluated the predictors of BSI and death within 60 days after the 
index UTI. The Kaplan–Meier curves for time to death within 60 days were first constructed 
and stratified by the exposure to antibiotics and the use of the two first-line antibiotics 
(trimethoprim and nitrofurantoin) at the first GP visit. After ensuring the proportional hazard 
assumptions were met, the curves were then compared using the log-rank test to assess 
significance. The main predictor analysed for this study was the antibiotic exposure. 
A multivariable logistic regression analysis was performed to assess the associations between 
antibiotic exposure and BSI, while a multivariable Cox regression analysis was used to assess 
the association between antibiotic exposure and all-cause mortality within 60-days post UTI 
diagnosis. The distinct episodes of UTI within the same individual are likely to be correlated 
with each other, which may affect the apparent relationship between exposure and outcome. 
Not accounting for intra-cluster correlation and assuming independence between episodes 
may lead to smaller standard errors and thus narrower confidence intervals for the parameter 
estimates. Therefore, the robust standard error approach was used in both logistic and Cox 
regression models to derive standard errors that allow for the clustering.  
 
A sensitivity analysis was subsequently undertaken to assess the risks of outcomes selected 
with exposure to ‘any antibiotic’ for any duration. The sensitivity analyses were restricted to 
antibiotic treatment with durations below both 21 days and 28 days to target only curative 
therapy (as longer duration of antibiotics was likely to be prescribed as prophylactic 
treatment).  
All the statistical analyses were performed using STATA version 12 (STATA Corp, College 
Station, Texas). 
 
Patient and public involvement  
This project was developed within a context of strong patient and public involvement already 
established within our research team, university and trust. Two former patients aged 65 and 
above reviewed the protocol. Their input helped to refine the research question and to improve 
significantly the protocol. The dissemination plan targets a wide audience including members 
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of the public, patients, health professionals and experts in the field through various channels 
available:  written communication, events and conferences, networks and social media. 
Results 
Overall, 1,577,324 observations relating to a primary care UTI consultation between November 
1, 2007 and May 31, 2015 for patients aged 65 and above were extracted from the CPRD 
database. After applying our exclusion criteria and removing all duplicates, our analytic sample 
included a total of 312,896 distinct UTI episodes diagnosed among 157,264 unique patients. 
An average of 2 episodes of UTI per patient was observed in this cohort (Figure 2).  
 
Figure 2: Flow chart of study cohort 
 
The mean age of the study cohort was 77 years (SD 9.16). At the time of the initial UTI 
diagnosis, 246,630 (79%) cases were female, 40% originated from the South of England and 
about 29% were from the most deprived areas (4th and 5th IMD quintiles). Less than 25% of 
the cases had a Charlson Comorbidity Index equal to or above 1. About 22% of the cases had 
recurrent UTIs as defined above (Table 1).  
About 7% of the UTI episodes did not have a record of an antibiotic prescription in primary 
care and 6% showed a delay in antibiotic prescribing. For UTI episodes where antibiotics were 
prescribed, 74% received trimethoprim (55%) or nitrofurantoin (19%); cephalosporins or 
amoxicillin/clavulanic acid were prescribed in about 10% of the episodes each, while 
quinolones were prescribed in less than 5%. About 0.4% of the episodes were prescribed 
pivmecillinam, which was only included among recommended first-line treatments in PHE 
guidelines in October 2014 (Table 2).27 
Patients older than 85 years, living in a deprived area, with a high Charlson Comorbidity Score, 
were mainly managed using either the ‘deferred antibiotics’ or ‘no antibiotics’ approach, while 
patients aged between 65 and 74 years-old were mainly prescribed ‘immediate antibiotics’. The 
ratio Female:Male was also much higher in the ‘immediate’ antibiotics group compared with 
the other groups. A course of antibiotics was more often prescribed at the first GP visit or with 
a delay in patients experiencing recurrent UTIs as defined previously. Patients who were 
prescribed antibiotics or were discharged to the hospital within 30 days prior to the index UTI 
event were more often prescribed ‘deferred antibiotics’ or ‘no antibiotics’ (Table 1). 
About 7.5% of the UTI episodes involved at least one of a range of specific or non-specific 
signs/symptoms within 30 days prior to the index UTI infection. Pain, dysuria, micturition 
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frequency, incontinence and haematuria were the five most frequent symptoms encountered 30 
days before the patients were formally diagnosed with a UTI. More than 90% of the cases with 
these symptoms recorded were prescribed antibiotics. This proportion was lower for cases with 
non-specific signs such as confusion and malaise (78% and 87%, respectively) (Table 1). 
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Table 1: Summary of patients’ characteristics and outcomes related to each episode of UTI 
 
 Total UTI cases 
N=312,896 
Immediate antibiotics 
N=271,070 (86.63%) 
Deferred antibiotics 
N=19,292 (6.17%) 
No antibiotics 
N=22,534 (7.20%) 
P value 
Patient Characteristics      
Age years (Mean, SD) 76.68 (9.16) 76.27 (9.06) 79.05 (9.19) 79.32 (9.46) P<0.001 
65-74  n (%) 136,175 (43.52) 122,458 (45.18) 6,402 (33.18) 7,315 (32.46)  
75-84 n (%) 107,485 (34.35) 92,856 (34.26) 6,881 (35.67) 7,748 (34.38)  
≥85 n (%) 69,236 (22.13) 55,756 (20.57) 6,009 (31.15) 7,471 (33.15)  
Gender F:M (Ratio) 246,630:66,266 (3.72) 217,843:53,227 (4.09) 13,657:5,635 (2.42) 15,130:7,404 (2.04) P<0.001 
Region n (%)      
North of England & Yorkshire 65,649 (20.98) 56,744 (20.93) 4,178 (21.66) 4,727 (20.98)  
Midlands & East of England 89,337 (28.55) 76,695 (28.29) 5,809 (30.11) 6,833 (30.32  
South of England 126,215 (40.34) 110,123 (40.63) 7,457 (38.65) 8,635 (38.32)  
London 31,695 (10.13)  27,508 (10.15) 1,848 (9.58) 2,339 (10.38) P<0.001 
Index Multiple Deprivation n (%)      
1st quintile (least deprived) 77,945 (24.60) 67,081 (24.76) 4,668 (24.21) 5,196 (23.07)  
2 75,949 (24.28) 66,084 (24.39) 4,589 (23.80) 5,276 (23.42)  
3 69,407 (22.19) 60,277 (22.25) 4,193 (21.75) 4,937 (21.92)  
4 51,396 (16.43) 44,239 (16.33) 3,229 (16.75) 3,928 (17.44)  
5th quintile (most deprived) 39,068 (12.49) 33,279 (12.28) 2,603 (13.50) 3,186 (14.15) P<0.001 
Charlson Comorbidity Index (CCI) 
(Mean, SD) 
0.36 (0.75) 0.35 (0.74) 0.44 (0.85) 0.44 (0.86) P<0.001 
CCI≥1 75,563 (24.24) 63,694 (23.63) 5,492 (28.53) 6,377 (27.88) P<0.001 
Immunosuppressed 82 (0.03) 67 (0.02) 8 (0.04) 7 (0.03) 0.348 
Renal diseases 10,215 (3.26) 8,588 (3.17) 746 (3.87) 881 (3.91) P<0.001 
Smoking 12,449 (3.98) 10,798 (3.98) 751 (3.89) 900 (3.99) 0.818 
Recurrent UTI 68,967 (22.04) 59,456 (21.93) 6,072 (31.47) 3,439 (15.26) P<0.001 
Indwelling urethral catheter 2,627 (0.84) 1,933 (0.71) 352 (1.82) 342 (1.52) P<0.001 
Hospitalisation within 30 days 
prior to UTI diagnosis n (%) 
35,825 (11.45) 22,930 (8.46) 5,252 (27.22) 7,643 (33.92) P<0.001 
Antibiotics exposure 30 days prior 
to UTI diagnosis n(%) 
61,832 (19.76) 49,079 (18.11) 7,173 (37.18) 5,580 (24.76) P<0.001 
Symptoms within 30 days prior to 
UTI diagnosis n (%)** 
23,502 (7.51) 19,172 (7.07) 2,021 (10.48) 2,309 (10.25) P<0.001 
13 
 
 Total UTI cases 
N=312,896 
Immediate antibiotics 
N=271,070 (86.63%) 
Deferred antibiotics 
N=19,292 (6.17%) 
No antibiotics 
N=22,534 (7.20%) 
P value 
Enuresis 13 (0.01) 10 (76.92) 3 (23.08) 0  
Urine Smell 50 (0.02) 43 (86) 5 (10) 2 (4)  
Urgency 397 (0.13) 348 (87.66) 23 (5.79) 26 (6.55)  
Malaise 688 (0.22) 527 (76.60) 69 (10.03) 92 (13.37)  
Fatigue 694 (0.22) 607 (87.46) 39 (5.62) 48 (6.92)  
Confusion 1,459 (0.47) 895 (61.34) 241 (16.52) 323 (22.14)  
Haematuria 2,065 (0.66) 1,621 (78.50) 205 (9.93) 239 (11.57)  
Incontinence 2,159 (0.69) 1,783 (82.58) 194 (8.99) 182 (8.43)  
Micturition frequency 3,682 (1.18) 3,151 (85.58) 261 (7.09) 270 (7.33)  
Dysuria 4,158 (1.33) 3,411 (82.03) 398 (9.57) 349 (8.39)  
Pain* 9,604 (3.07) 7,896 (82.22) 746 (7.77) 962 (10.02)  
Outcome      
BSI n (%; CI95) 1,539 (0.49; 0.47 to 
0.52) 
479 (0.18; 0.16 to 0.19) 413 (2.15; 1.94 to 2.35) 647 (2.87; 2.65 to 3.09) P<0.001 
Hospitalisation n (%; CI95) 51,261  
(16.38; 16.25 to 16.51) 
40,022  
(14.76; 14.63 to 14.90) 
5,165  
(26.77; 26.15 to  27.40) 
6,074  
(26.95; 26.38 to 27.53) 
P<0.001 
Length of stay in days (mean, SD) 7.09 (15.01) 6.26 (13.98) 7.68 (13.23) 12.11 (20.85) P<0.001 
Death 60 days n (%; CI95) 6,193 (1.98; 1.93 to 
2.03) 
4,431 (1.63; 1.59 to 
1.68) 
545 (2.83; 2.59 to 3.06) 1,217 (5.40; 5.11 to 5.70) P<0.001 
*Pain in locations linked with UTI excluding dysuria 
**Number of UTI episodes where patients reported having at least one symptom within 30 days before the UTI diagnosis. Patients may report one or more symptoms, so the 
number of episodes per symptom aggregated across all symptoms differ from the total of episodes experiencing one or more symptoms (which is presented above). In this 
section, all but the 1st column are row % which differ from the rest of the table.  
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Table 2: Distribution of antibiotics prescriptions among patients prescribed 
‘immediate’ treatment during their index UTI visit 
 
Overall, 1,539 episodes of BSI (0.5% of the total number of UTIs) were recorded in the CPRD 
and/or HES databases within 60 days following a diagnosis of UTI in older adult patients 
between 2007-2015. The rate of BSI significantly increased when patients were not prescribed 
antibiotics for their UTI (2.9% versus 0.2% for ‘immediate antibiotics’ and 2.2% for ‘deferred 
antibiotics’, p<0.001). After adjusting for covariates, patients in the ‘deferred antibiotics’ and 
‘no antibiotics’ groups were significantly more likely to experience a BSI within 60 days 
compared with the ‘immediate antibiotics’ group (adjusted odd ratio [aOR] 7.12 [95% CI 6.22 
to 8.14] and 8.08 [95% CI 7.12 to 9.16], respectively) (Table 3). 
The NNH estimate for BSI was lower (greater risk) with ‘no antibiotics’ (NNH=37) than with 
‘deferred antibiotics’ (NNH=51), which means that on average for every 37 patients exposed 
to ‘no antibiotics’ and for every 51 patients exposed to ‘deferred antibiotics’, 1 case of BSI 
would occur that would not have been seen with ‘immediate antibiotics’. No significant 
difference was observed between the rate of BSI for ‘immediate’ trimethoprim treatment 
(233/148,333: 0.2%) and nitrofurantoin treatments (90/51,745: 0.2%, p=0.41).  
 
 
  
Antibiotics N (%) 
Trimethoprim 148,333 (54.72) 
Nitrofurantoin 51,745 (19.09) 
Cephalosporins 31,090 (11.47) 
Amoxicillin/ Clavulanic Acid 25,616 (9.45) 
Quinolones 11,995 (4.43) 
Pivmecillinam 1,084 (0.40) 
Macrolides 747 (0.28) 
Penicillinase-resistant penicillins 323 (0.12) 
Benzylpenicillin and 
phenoxymethylpenic 
70 (0.03) 
Aminoglycosides 27 (0.01) 
Clindamycin 3 (<0.01) 
Carbapenems 3 (<0.01)  
Polymyxin 1 (<0.01) 
Total 271,070 
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Table 3: Multivariable Logistic Regression analysis for 60-day post diagnosis BSI 
 Unadjusted Odd Ratio 
(95% Conf. Interval)* 
P>|z| Adjusted** Odd Ratio 
(95% Conf. Interval)* 
P>|z| 
Antibiotic Exposure     
Antibiotic first visit Ref  Ref  
Deferred antibiotic 12.36 (10.81 to14.13) <0.001 7.12 (6.22 to 8.14) <0.001 
No antibiotics 16.70 (14.81 to 18.83) <0.001 8.08 (7.12 to 9.16) <0.001 
Age (years)     
65-74  Ref  Ref  
75-84  2.37 (2.08 to 2.71) <0.001 1.59 (1.39 to 1.82) <0.001 
≥85  3.13 (2.73 to 3.58) <0.001 1.67 (1.44 to 1.93) <0.001 
Gender     
Male Ref  Ref  
Female 0.25 (0.23 to 0.28) <0.001 0.45 (0.40 to 0.50) <0.001 
Region     
North of England & 
Yorkshire 
Ref    
Midlands & East of 
England 
1.02 (0.89 to 1.18) 0.74   
South of England 0.86 (0.75 to 0.99) 0.03   
London 0.90 (0.74 to 1.09) 0.28   
Index Multiple 
Deprivation 
    
1st quintile (least 
deprived) 
Ref  Ref  
2 1.00 (0.86 to 1.16) 0.98 0.97 (0.83 to 1.14) 0.74 
3 1.07 (0.92 to 1.25) 0.38 1.04 (0.89 to 1.22) 0.58 
4 1.35 (1.15 to 1.58) <0.001 1.21 (1.03 to 1.42) 0.02 
5th quintile (most 
deprived) 
1.39 (1.18 to 1.65) <0.001 1.18 (0.99 to 1.40) 0.06 
Charlson Comorbidity 
Score [0-12] 
1.35 (1.29 to 1.40) <0.001 1.10 (1.04 to 1.16) <0.001 
Immunosuppressed  5.06 (1.26 to 20.31) 0.02   
Renal diseases  1.61 (1.28 to 2.02) <0.001   
Smoking  1.20 (0.95 to 1.52) 0.16   
Year of UTI      
2007/2008 Ref  Ref  
2008/2009 0.70 (0.45 to 1.10) 0.12 0.67 (0.42 to 1.07) 0.09 
2009/2010 0.74 (0.48 to 1.16) 0.20 0.66 (0.42 to 1.05) 0.08 
2010/2011 0.97 (0.63 to 1.51) 0.90 0.86 (0.55 to 1.36) 0.53 
2011/2012 0.90 (0.58 to 1.40) 0.65 0.77 (0.49 to 1.22) 0.26 
2012/2013 1.98 (1.30 to  3.01) 0.001 1.57 (1.01 to 2.42) 0.04 
2013/2014 3.38 (2.24 to  5.12) <0.001 2.72 (1.77 to 4.19) <0.001 
2014/2015 4.52 (2.98 to 6.83) <0.001 3.46 (2.25 to 5.32) <0.001 
Symptoms within 30 
days prior UTI 
diagnosis 
1.20 (1.01 to 1.44) 0.04   
Antibiotic prescribed 
within 30days prior 
to the UTI diagnosis  
1.26 (1.12 to 1.42) <0.001   
Hospitalisation 30 
days before diagnosis 
10.45 (9.44 to 11.57) <0.001 3.94 (3.54 to 4.39) <0.001 
Indwelling urethral 
catheter  
3.60 (2.66 to  4.89) <0.001   
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 Unadjusted Odd Ratio 
(95% Conf. Interval)* 
P>|z| Adjusted** Odd Ratio 
(95% Conf. Interval)* 
P>|z| 
Recurrent UTIs 0.77 (0.67 to 0 .88) <0.001 0.86 (0.75 to 0.99) 0.04 
Interaction antibiotic 
exposure and 
recurrence 
1.27 (1.15 to 1.41) <0.001   
* Standard Errors adjusted for clustering using the robust standard errors approach 
** All the variables showing a p value <0.2 in the univariate analyses (unadjusted results) were included and 
tested in the multivariable logistic regression model (adjusted results). 
 
The proportion of UTI cases admitted to the hospital following an episode of UTI was nearly 
two times higher for cases in the ‘no antibiotics’ (27%) and ‘deferred antibiotics’ (27%) groups 
compared with those with ‘immediate antibiotics’ (15%). Among cases admitted to hospital, 
the length of stay was significantly higher for the ‘no antibiotics’ group (12.1 days versus 6.3 
days for ‘immediate antibiotics’ group and 7.7 days for ‘deferred antibiotics’ group) (Table 1).  
 
Finally, about 2.0% of the UTI cases over 65 years who presented to their GP with a UTI died 
within 60 days (5.4% for ‘no antibiotics’, 2.8% for ‘deferred antibiotics’ and 1.6% for 
‘immediate antibiotics’) (Table 1). The NNH estimate for death within 60 days was lower with 
‘no antibiotics’ (NNH=27) than with ‘deferred antibiotics’ (NNH=83) with a calculated risk 
relative to ‘immediate antibiotics’. The Kaplan Meier curves demonstrated a significant 
reduction of the 60-day survival for older adult patients prescribed ‘no antibiotics’ or ‘deferred 
antibiotics’ compared with those prescribed ‘immediate antibiotics’ (Figure 3A). Among the 
patients who were prescribed ‘immediate’ antibiotics, a small but significant reduction of the 
60-day survival was also observed for patients treated with trimethoprim (98.5%) compared 
with nitrofurantoin (98.7%, p<0.001) (Figure 3B). 
 
Figure 3: Kaplan Meier Survival Curves by antibiotics management over 60 days 
17 
 
The multivariable Cox regression analysis showed that the risk of all-cause mortality in older 
adults at any time during the 60 days follow-up was 1.16 and 2.18 times higher with ‘deferred 
antibiotics’ and ‘no antibiotics’, respectively, after adjusting for covariates, compared with 
‘immediate antibiotics’ (adjusted Hazard Ratio (aHR)=1.16 [95% CI, 1.06 to 1.27] and 
aHR=2.18 [95% CI, 2.04 to 2.33], respectively) (Table 4).  The sensitivity analyses excluding 
the antibiotic treatments with a duration above 21 days and 28 days from the analyses showed 
consistent results. However, the magnitude of the associations between treatment groups were 
slightly higher for those who were prescribed ‘deferred antibiotics’ (aHR=1.19 [95% CI 1.14 
to 1.23]; aHR=1.36 [95% CI 1.22 to 1.48], respectively) and ‘no antibiotics’ (aHR=2.47 [95% 
CI 2.28 to 2.63]; (aHR=2.61 [95% CI 2.38 to 2.75]), compared with those prescribed 
‘immediate antibiotics’. 
 
In the multivariable Cox regression model, being older, male, living in a deprived area, having 
a higher Charlson comorbidity score, being a smoker, being immunosuppressed, having renal 
disease and having been exposed to antibiotics and/or discharged from hospital 30 days prior 
to the UTI diagnosis, were all positively associated with 60-day all-cause mortality. In contrast, 
living in London or South England compared with the North of England and Yorkshire or the 
East of England and Midlands, as well as having recurrent UTIs, were significantly associated 
with a decrease in mortality. The interaction factor between antibiotic exposure and recurrent 
UTIs was also significant and thus included in the final multivariable model (Table 4). 
 
Table 4: Multivariable Cox Regression analysis for 60-day post UTI diagnosis all-cause 
mortality 
 Unadjusted Hazard Ratio 
(95% Conf. Interval)* 
P>|z| Adjusted** Hazard Ratio 
(95% Conf. Interval)* 
P>|z| 
Antibiotic Exposure     
Antibiotic first visit Ref  Ref  
Deferred antibiotic 1.73 (1.59 to 1.89) <0.001 1.16 (1.06 to 1.27) 0.001 
No antibiotics 3.38 (3.17 to 3.60) <0.001 2.18 (2.04 to 2.33) <0.001 
Age (years)     
65-74 Ref  Ref  
75-84 3.20 (2.94 to 3.48) <0.001 2.79 (2.60 to 2.99) <0.001 
≥85 9.42 (8.71 to 10.19) <0.001 7.87 (7.37 to 8.40) <0.001 
Gender     
Male Ref  Ref  
Female 0.42 (0.40 to 0.44) <0.001 0.52 (0.49 to 0.55) <0.001 
Region     
North of England & 
Yorkshire 
Ref  Ref  
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 Unadjusted Hazard Ratio 
(95% Conf. Interval)* 
P>|z| Adjusted** Hazard Ratio 
(95% Conf. Interval)* 
P>|z| 
Midlands & East of 
England 
0.98 (0.92 to 1.06) 0.67 0.97 (0.90 to 1.04) 0.39 
South of England 0.93 (0.87 to 0.99) 0.025 0.93 (0.87 to 1.00) 0.05 
London 0.69 (0.62 to 0.77) <0.001 0.72 (0.65 to 0.80) <0.001 
Index Multiple 
Deprivation 
    
1st quintile (least 
deprived) 
Ref  Ref  
2 1.17 (1.08 to 1.26) <0.001 1.16 (1.07 to 1.26) <0.001 
3 1.31 (1.22 to 1.42) <0.001 1.27 (1.18 to 1.37) <0.001 
4 1.29 (1.19 to 1.40) <0.001 1.29 (1.19 to 1.40) <0.001 
5th quintile (most 
deprived) 
1.35 (1.23 to 1.47) <0.001 1.33 (1.21 to 1.45) <0.001 
Charlson Comorbidity 
Score [0-12] 
1.50 (1.47 to 1.53) <0.001 1.27 (1.21 to 1.33) <0.001 
Immunosuppressed  5.26 (2.60 to 10.65) <0.001 5.09 (2.54 to 10.20) <0.001 
Renal diseases  2.00 (1.81 to 2.22) <0.001 1.81 (1.72 to 1.93) 0.002 
Smoking  0.82 (0.71 to 0.94) 0.005 1.27 (1.10 to 1.46) 0.001 
Year of UTI      
2007/2008 Ref  Ref  
2008/2009 1.20 (1.00 to 1.45) 0.05 1.14 (0.94 to 1.37) 0.18 
2009/2010 1.17 (0.97 to 1.41) 0.09 1.09 (0.89 to 1.30) 0.42 
2010/2011 1.25 (1.04 to 1.51) 0.02 1.13 (0.92 to 1.36) 0.27 
2011/2012 1.29 (1.07 to 1.55) 0.008 1.09 (0.91 to 1.32) 0.36 
2012/2013 1.50 (1.25 to 1.81) <0.001 1.23 (1.02 to 1.48) 0.02 
2013/2014 1.55 (1.29 to 1.87) <0.001 1.24 (1.03 to 1.50) 0.02 
2014/2015 1.58 (1.30 to 1.91) <0.001 1.23 (1.02 to 1.48) 0.04 
Symptoms within 30 
days prior UTI 
diagnosis 
1.23 (1.13 to 1.34) <0.001   
Antibiotic prescribed 
within 30days prior to 
the UTI diagnosis  
1.50 (1.42 to 1.58) <0.001 1.31 (1.22 to 1.42) <0.001 
Hospitalisation 30 days 
before diagnosis 
3.24 (3.07 to 3.42) <0.001 1.88 (1.77 to 2.03) <0.001 
Indwelling urethral 
catheter  
2.71 (2.29 to 3.21) <0.001   
Recurrent UTIs 0.92 (0.87 to 0.98) 0.008 0.89 (0.82 to 0.95) <0.001 
Interaction antibiotic 
exposure and 
recurrence 
1.11 (1.06 to 1.17) <0.001 1.19 (1.10 to 1.30) <0.001 
* Standard Errors adjusted for clustering using the robust standard errors approach  
** All the variables showing a p value <0.2 in the univariate analyses (unadjusted results) were included and 
tested in the multivariable Cox regression model (adjusted results). 
 
Finally, for the care pathway of older adults diagnosed with UTI in primary care, about 45% 
of UTI cases (n=139,359) presented only once to the GP without a subsequent hospital 
admission, while 38% (n=119,364) required multiple visits to the GP for the same UTI episode 
and 17% (n=54,173) were admitted to hospital within 60 days of their first UTI visit. Among 
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cases who were not prescribed antibiotics, about 29% were admitted to the hospital or died 
within 60 days, compared with 16% among those who were prescribed antibiotics; 27% of men 
were hospitalised or died within 60 days compared with 15% of women. Older patients were 
more likely to be hospitalised compared with 65-74 years-old cases who were more likely to 
have a single visit to the GP (Table 5).   
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Table 5: Care pathway of each UTI episode experienced by older adult patients diagnosed in primary care 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
* ‘Deferred’ and ‘immediate’ antibiotic approaches were merged together in the ‘antibiotics’ group 
  Single GP visit Multiple GP visits Hospitalisation including 
death within 60 days 
P value 
Antibiotic 
exposure* 
N (%; CI95) 
No antibiotics 
N=22,534  
(7.20; 7.11 to 7.29) 
14,722  
(65.33; 64.71 to 65.95) 
1,175 
(5.21; 4.92 to 5.50) 
6,637 
(29.45; 28.86 to 30.05) 
 
 
 Antibiotics 
N=290,362  
(92.80; 92.71 to  92.89) 
124,637  
(42.92; 42.74 to 43.10) 
118,189 
(40.70; 40.53 to 40.88) 
47,536 
(16.37; 16.24 to 16.51) 
<0.001 
Gender 
N (%; CI95) 
Male 
N=66,266  
(21.18; 21.04 to 21.32) 
24,561  
(37.06; 36.70 to 37.43) 
23,640 
(35.67; 35.31 to 36.04) 
18,065 
(27.26; 26.92 to 27.60) 
 
 Female 
N=246,630  
(78.82; 78.68 to 78.96) 
114,798  
(46.55; 46.35 to 46.74) 
95,724 
(38.81; 38.62 to 39.01) 
36,108 
(14.64; 14.50 to 14.78) 
<0.001 
Age 
N (%; CI95) 
65-74 years 
N=136,175  
(43.52; 43.35 to 43.69) 
66,972  
(49.18; 48.92 to 49.45) 
 
51,336 
(37.70; 37.44 to 37.96) 
 
17,867 
(13.12; 12.94 to 13.30) 
 
 
 75-84 years 
N=107,485  
(34.35; 34.19 to 34.52) 
45,909  
(42.71; 42.42 to 43.01) 
41,427 
(38.54; 38.25 to 38.83) 
20,149 
(18.75; 18.51 to 18.98) 
 
 ≥85 years 
N=69,236  
(22.13; 21.98 to 22.27) 
26,478  
(38.24; 37.88 to 38.61) 
26,601 
(38.42; 38.06 to 38.78) 
16,157 
(23.34; 23.02 to 23.65) 
<0.001 
Total 
N (%; CI95) 
N=312,896 139,359  
(44.54; 44.36 to 44.71) 
119,364 
(38.15; 37.98 to 38.32) 
54,173 
(17.31; 17.18 to 17.45) 
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Discussion 
Main findings 
This study has shown that patients aged over 65 years diagnosed with a UTI in the community 
were at significantly increased risk of BSI and death within 60 days when antibiotic treatment 
was either not prescribed or deferred.  
 
The odds of developing a BSI within 60 days was 7 and 8 times higher in the ‘deferred 
antibiotics’ and the ‘no antibiotics’ groups, respectively, compared with the ‘immediate 
antibiotics’ group. The NNH for BSI was lower with ‘no antibiotics’ (NNH=37) than with 
‘deferred antibiotics’ (NNH=51), both relative to ‘immediate antibiotics’. Patients in the ‘no 
antibiotics’ group were also more than twice as likely to die, while patients in the ‘deferred 
antibiotics’ group were 1.16 as likely to die during the 60 days following a UTI, compared with 
those in the ‘immediate antibiotic’ prescription. The NNH estimate for death was lower with 
‘no antibiotics’ (NNH=27) than with ‘deferred antibiotics’ (NNH=83).  
 
These findings were adjusted for potential confounding factors and changes over time to 
account for national guidelines updates. The risk of BSI and all-cause mortality also increased 
for male and older patients, especially those aged over 85 years, and those living in more 
deprived areas. Among patients who were prescribed ‘immediate antibiotics’ for an episode of 
UTI, a small but significant increase of the 60-day survival was observed for those treated with 
nitrofurantoin compared with trimethoprim. This increase may either reflect higher levels of 
resistance to trimethoprim16 or a healthier population treated with nitrofurantoin; the latest 
being not recommended for patients with poor kidney function.28 These results are consistent 
with a recent cohort study using CPRD, where nitrofurantoin was associated with the smallest 
odds of death within 14 days of antibiotic initiation for UTI of all the antibiotics investigated.29 
Strengths and limitations of study 
Strengths 
Our study exhibits several strengths. A major strength is the use of individual patient-level data 
for adults aged over 65 years extracted from a large nationwide general practice records 
database and linked to hospital and mortality records. This provided the opportunity to track 
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the care pathways of a vulnerable population diagnosed with a UTI in the community with a 
60-day follow-up. The linkage with mortality data from the Office of National Statistics 
minimised possible bias in the risk estimates of all-cause mortality among older adult patients 
treated in a routine care setting.  
The large sample size of approximately 160,000 patients with more than 300,000 distinct UTI 
episodes significantly increased the power of the analyses, especially for rare severe adverse 
events in older adult patients (i.e. BSI, mortality). As the base population is representative of 
the English general population, our results are generalisable to the entire English elderly patient 
population.  
In addition, records were routinely collected by GPs in normal care settings providing an 
unbiased selection of both the exposed and control cohorts and reducing the opportunity for 
information bias (as exposure and outcomes were prospectively collected independently). This 
study did not only help us to understand the management of UTI in an older population in ‘real 
life’ but enabled us to assess the ‘no antibiotic’ treatment approach for UTI. This option would 
have been challenging in a prospective trial due to ethical restraints. Finally, we had access to 
detailed patient information, including patient diagnoses, comorbidities, prescribed 
medications and procedures allowing us to control for the effects of several potential 
confounders in the multivariable regression models. 
Limitations 
The main limitations of our study are common to observational studies using routinely 
collected electronic health record data, and include unmeasured and residual confounders, 
missing data and potential biases, such as confounding by indication, misclassification biases 
or inconsistencies in coding within and between practices and over time.  
 
Patients were identified and included in our study based on a clinical diagnosis recorded using 
a coding system. Therefore, most of the cases were suspected UTIs, with only a minority based 
on a laboratory-confirmed diagnosis. Separate microbiology data with UTI confirmation and 
drug sensitivities were unavailable. We have used a pragmatic approach to include all the 
possible descriptors a GP might use for infectious disease of the urinary tract. Further research 
using a more specific list of codes for UTI could be worth exploring. 
 
The uncertainties around the UTI diagnosis in the elderly patients due to uncommon 
presentations may have biased the selection of our initial UTI cohort of patients. A variety of 
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acute infectious or non-infectious causes leading to those uncertainties may have driven the 
adverse outcomes. The CPRD database only reports the symptoms documented by the GPs and 
does not always include a structured assessment of the illness with information on symptoms 
severity and onset for example, which made the control for confounding by indication difficult. 
However, we may have observed that the protective effect of the ‘immediate antibiotics’ would 
exceed the effect of confounding by indication as previously described by Little et al. 30 
 
There were potential classification biases for the exposure variable associated with the lack of 
information on treatment compliance by the patients and on delayed prescriptions issued by 
GPs at the index visit in CPRD database. The database did not define whether the prescribed 
antibiotics dated on the date of the initial UTI diagnosis had to be taken immediately or several 
days later in the context of ongoing symptoms. This common delayed prescription strategy to 
reduce inappropriate antibiotic prescribing, as well as patients who did not consume the 
antibiotics prescribed by the GPs, may have incorrectly classified some patients as belonging 
to the ‘immediate antibiotics’ group. Conversely the database did not identify patients who had 
already accessed antibiotics (rescue pack or previous prescription). This ’might partly explain 
the observation Table 1 that more patients in the ‘deferred’ and ‘no antibiotics’ groups had 
received antibiotics or had been admitted to the hospital in the previous month compared with 
the ‘immediate antibiotics’ group. We also did not consider the number of days between the 
date of the initial UTI diagnosis and the date of ‘deferred antibiotics’ when a prescription was 
not issued at the index visit, which may have an impact on the adverse outcomes.  
 
We cannot exclude an alternative non-urinary source for the BSIs. The origin of the BSIs is not 
often specified in the HES or CPRD database. In the context of the cohort of patients in this 
study having initially been diagnosed with a UTI in primary care, most of the BSIs recorded 
should have a urinary source. Reverse causality was unlikely in this study as we have tried to 
make sure that the date of the exposure (antibiotic management) was before the outcomes (BSIs 
and/or mortality). 
 
Finally, the complexity of the coding system in electronic health record databases, the 
variability in recording information, as well as missing data, may have also prevented us from 
capturing a comprehensive list of the complications related to UTI and the confounders 
associated with increased risk of BSI and all-cause mortality. For example, some nursing 
homes may have a wait and see policy for antibiotic prescribing to prevent Clostridium difficile 
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outbreaks. It is also possible that patients with cognitive impairment may lack insight into the 
severity of their illness and haven’t been prescribed antibiotics while it was needed. By 
adjusting our outcomes on existing comorbidities using the Charlson Comorbidity Index, we 
have however tried to minimise the presence of some residual confounders.  
 
Comparison with existing literature 
 
This study is to our knowledge the first large sample size population-based observational cohort 
study, assessing the ‘real-life’ care management, including ‘no antibiotics’ and ‘deferred 
antibiotics’, as well as the outcomes and care pathway of the older adult patients diagnosed 
with UTI in primary care. Limited evidence is available to support the choice of ‘no antibiotics’ 
or ‘deferred antibiotics’ for the management of UTI in primary care as ethical concerns have 
prevented from conducting placebo-controlled studies for UTI.31  
A systematic review of randomised controlled trials (RCTs) has demonstrated that antibiotic 
treatment is more effective at achieving a faster symptom relief, microbiological clearance and 
lower reinfection rates than placebo for uncomplicated cystitis in women ranging from 15 to 
84 years-old.32 However, potential unintended adverse events have not been explored (e.g. 
hospitalisation, BSI or death) as a large sample size would be needed to capture these rare 
serious adverse events. Another RCT which evaluated the efficacy of initial symptomatic 
treatment with ibuprofen versus immediate antibiotic treatment in uncomplicated UTI for 
women below 65 years-old has shown an increase in the total burden of symptoms and 
pyelonephritis cases in the ibuprofen arm.33 
In the context of RCTs, strict exclusion criteria particularly related to age, have been applied 
which prevent the results being generalised to older adult populations who may require a 
different approach in the management of UTI. In contrast, our study has specifically looked at 
the group of older patients above 65 who are more susceptible to complications and often 
neglected in UTI-related research. We demonstrated that antibiotics prescribed at the time of 
UTI diagnosis may benefit this vulnerable population by significantly reducing the risk of all-
cause mortality and the rate of BSI and hospital admission.  
 Recent NICE guidance (National Institute of Health and Care Excellence) has proposed ‘no 
antibiotic’ or delayed antibiotic prescriptions when infection is likely to be self-limiting in the 
effort to reduce inappropriate prescribing.15 34 Evidence and recommendations, however, refer 
mainly to upper respiratory tract infections.30 35 There is emerging evidence, however, that 
delayed prescribing in the treatment of UTI is becoming more acceptable in practice.36 37 
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An RCT conducted by Little et al. 2010 has evaluated various antibiotic management 
strategies including empirical delayed (by 48 hours) antibiotics and ‘immediate antibiotics’ 
strategy for UTI in adult women below 70 years-old. No significant differences in symptom 
duration, severity or frequency of symptoms between the strategies were reported.38 In our 
study, ‘deferred antibiotics’ management is associated with less severe adverse outcomes 
than the ‘no antibiotics’ group for older adult patients, but still has a significantly higher risk 
of mortality compared with ‘immediate antibiotics’ therapy.  
The question remains why a significant proportion (~7%) of vulnerable older patients was 
diagnosed with UTI but not prescribed antibiotics. It could be patient or doctor choice, but it 
is also possible that antimicrobial stewardship programmes and quality premium payments 
are encouraging a culture of more judicious antibiotic use. A 13.2% reduction in antibiotic 
prescribing in primary care between 2013 and 2017 was recently reported by Public Health 
England.16 
There is also a significant concern regarding the risk of Clostridium difficile infection in the 
elderly associated with antibiotic exposure which also includes trimethoprim.39 40 
Other circumstances, such as the presence of mild urinary symptoms, may encourage the 
clinician to withhold antibiotics in the context of a working diagnosis of UTI. Nevertheless, if 
this explanation holds true, these individuals with disease not severe enough to prompt 
antibiotic therapy are at risk of severe consequences.  
 
Clinical, policy and research implications 
 
Our findings suggest that GPs consider early prescription of antibiotics for this vulnerable 
group of older adults, in view of their increased susceptibility to sepsis following UTI and 
despite a growing pressure to reduce inappropriate antibiotic use. Particular care is needed for 
the management of older men, and those in deprived communities. For researchers, there is a 
need to improve the understanding of the effects of ‘deferred’ prescribing in routine practice. 
New medical record or retrievable codes should therefore be in place to record when primary 
care clinicians advise patients to delay antibiotic consumption.  
 
Conclusion  
Results from this large population-based cohort study suggest a significant increase in the 
risk of BSI and all-cause mortality and the rate hospital admission associated with ‘no 
antibiotics’ and ‘deferred antibiotics’ approaches compared with ‘immediate antibiotics’ in 
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older adults diagnosed with UTI in primary care. Our study suggests the early initiation of 
antibiotics for UTI in older high-risk adult populations (especially male aged over 85) should 
be recommended to prevent serious complications.  
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